[PDF][PDF] DDX3X mediates EGFR-TKI resistance through VEGFR signaling
A Ohtsubo, H Kagamu, S Watanabe, K Shono… - 2021 - pdfs.semanticscholar.org
Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are
remarkably effective against non-small-cell lung cancer (NSCLC) with EGFR-activating …
remarkably effective against non-small-cell lung cancer (NSCLC) with EGFR-activating …
CRM1 inhibitors reduce primary and acquired resistance of EGFR inhibitors in lung cancer cells
W Gao - US Patent 11,266,624, 2022 - Google Patents
The present invention includes a method and compositions for preventing primary or
acquired resistance of epidermal growth factor receptors (EGFR) inhibitors in a cancer with …
acquired resistance of epidermal growth factor receptors (EGFR) inhibitors in a cancer with …
[PDF][PDF] OVERCOMING THE DRUG RESISTANCE OF EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS IN LUNG CANCER CELL LINES
LIU Zhongwei - 2018 - ttu-ir.tdl.org
Lung cancer is the leading cause of cancer-related deaths around the world with about 1.3
million deaths per year (Huang, 2014). Histologically, lung cancer can be classified into …
million deaths per year (Huang, 2014). Histologically, lung cancer can be classified into …
Development of 3D cancer cell models for pre-clinical research: evaluation of the tumour microenvironment in 3D stirred-systems
SC Veloso - 2014 - estudogeral.uc.pt
Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung
cancer (NSCLC) is the most frequent type of lung cancer, constituting approximately 85% off …
cancer (NSCLC) is the most frequent type of lung cancer, constituting approximately 85% off …
[PDF][PDF] DOCTEUR EN MÉDECINE
MP WISSLER - docnum.univ-lorraine.fr
Le cancer broncho-pulmonaire primitif est la 1 ère cause de mortalité par cancer en France.
L'espérance de vie à 5 ans est inférieure à 10%. Son principal facteur de risque est le tabac …
L'espérance de vie à 5 ans est inférieure à 10%. Son principal facteur de risque est le tabac …
Role of c-Met and EGFR synergism and identification of targets causing resistance to their inhibitors
JT Fong - 2012 - indigo.uic.edu
While the use of specific Tyrosine Kinase Inhibitors (TKIs) against epidermal growth factor
receptor (EGFR) and Hepatocyte Growth Factor Receptor (c-Met) in Non-Small Cell Lung …
receptor (EGFR) and Hepatocyte Growth Factor Receptor (c-Met) in Non-Small Cell Lung …
Erlotinib beim NSCLC: Wie entstehen Resistenzen?
S Krome - Onkologische Welt, 2012 - thieme-connect.com
Onkologische Welt 4/2012 Kapitel: Pneumo-Onkologie Page 1 Literatur 1. Mochizuki S et al.
Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand Factor. J Natl …
Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand Factor. J Natl …